-
By William T. Elliott, MD
-
The authors concluded that in a diverse, community-based population with new systolic heart failure, spironolactone did not reduce death or hospitalization, but did increase the incidence of hyperkalemia.
-
Among patients with mild-to-moderate Alzheimer's disease, 2000 IU/d of vitamin E resulted in a slower functional decline and a decrease in the caregiver burden.
-
A second sodium-glucose cotransporter 2 (sglt2) inhibitor has been approved for the treatment of adults with type 2 diabetes mellitus. These agents increase glucose secretion by inhibiting reabsorption in the kidney. Renal glucose threshold can be lowered to 70-90 mg/dL from a norm of 240 mg/dL in patients with diabetes. Dapagliflozin follows canagliflozin as the second SGLT2 approved and is marketed by Bristol-Myers Squibb and AstraZeneca as Farxiga.
-
-
-
-
-
A broad array of new federal regulations on health care associated infections (HAIs) continue to come on line in 2014 and beyond, tying infection prevention more directly to the hospital bottom line than at any time in the field's history.
-
Targeting HCWs for all ACIP recommended shots
